Divi's Laboratories Limited

August 01, 2026

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
Mumbai – 400 051

Trading Symbol: **DIVISLAB**

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Scrip Code: **532488**

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on August 01, 2026

Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Further to our letter dated July 20, 2026, we would like to inform that the Board of Directors of the Company at its meeting held on August 01, 2026, has approved, inter alia, the following items of business:

<u>Financial Results</u>

Approved the unaudited financial results for the quarter ended June 30, 2026. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Statement of unaudited standalone financial results for the quarter ended June 30, 2026 and Limited Review Report of the Statutory Auditors thereon.
2. Statement of unaudited consolidated financial results for the quarter ended June 30, 2026, and Limited Review Report of the Statutory Auditors thereon.
3. Press release on financial results.

<u>Appointment of Senior Management Personnel</u>

Approved appointment of Mr. B. Vara Prasad, General Manager (Engineering Purchase) and Mr. J. Srinivasa Rao, General Manager (Raw Materials Purchase) as Senior Management Personnel of the Company as recommended by the Nomination and Remuneration Committee, with effect from August 01, 2026.

The details required under Regulation 30 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as **Annexure – I.**

The Board meeting commenced at 10.15 Hrs and concluded at 11.20 Hrs.

This is for your information and records.

Thanking you,
Yours faithfully,
For Divi's Laboratories Limited

SATISH CHOUDHURY MEKA
Digitally signed by SATISH CHOUDHURY MEKA
Date: 2026.08.01 11:25:32 +05'30'

M. Satish Choudhury
Company Secretary & Compliance Officer

DIVI'S LABORATORIES LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2026

(₹ in Crores)

S. No.	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)**	(Unaudited)	(Audited)
1	**Income**				
	Revenue from operations	**2974**	2793	2357	10388
	Other income	**63**	154	119	506
	Total income	**3037**	2947	2476	10894
2	**Expenses**				
	a) Cost of materials consumed	**1495**	1173	989	4260
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress, and stock-in-trade	**(567)**	(70)	(72)	(244)
	d) Employee benefits expense	**397**	370	330	1400
	e) Depreciation and amortization expense	**132**	120	112	461
	f) Finance costs	**6**	6	3	23
	g) Other expenses	**409**	377	367	1484
	Total expenses	**1872**	1976	1729	7384
3	**Profit before exceptional items and tax (1-2)**	**1165**	971	747	3510
4	Exceptional items - Impact of New Labour codes	-	-	-	74
5	**Profit before tax (3-4)**	**1165**	971	747	3436
6	Tax expense				
	a) Current tax	**290**	250	191	869
	b) Deferred tax	**(16)**	(35)	(1)	(40)
	Total tax expense	**274**	215	190	829
7	**Profit for the period (5-6)**	**891**	756	557	2607
8	**Other comprehensive income:**				
	Items that will not be reclassified to Profit or Loss:				
	(i) Gain/(Loss) on Remeasurement of post-employment benefit obligation	**2**	(8)	(1)	8
	(ii) Income tax relating to the above	(1)	2	-*	(2)
	Total other comprehensive income (i+ii)	**1**	(6)	(1)	6
9	**Total comprehensive income (7+8)**	**892**	750	556	2613
10	Paid-up Equity Share Capital	**53**	53	53	53
11	Other equity excluding revaluation reserve				16658
12	Earnings per Share # (Face Value Rs.2/- each) (not annualized)				
	a) Basic (Rs.)	**33.55**	28.44	20.95	98.19
	b) Diluted (Rs.)	**33.55**	28.44	20.95	98.19

Earnings per share calculated on actual amount of profit after tax in rupees

*Amount is below the rounding off norms adopted by the company.

Notes:

1. The above Statement of standalone unaudited financial results for the quarter ended 30th June, 2026 ("Standalone statement") is prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Standalone statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 01, 2026. The statutory auditors have carried out a limited review of the Standalone statement and issued an unmodified report thereon.
2. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108.
3. The Company does not have any discontinued operations and the profit for the period represents profits from continuing operations only.
4. **Financial results for the quarter ended 31.03.2026 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year, which were subjected to limited review.
5. Details of Forex gain/(loss) are as given below: (₹ in Crores)

	Quarter Ended			Year Ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
Forex gain/(loss)	**(7)**	89	39	210

Forex gain has been included in other income and loss has been included in other expenses.

Price Waterhouse Chartered Accountants LLP
LLPIN AAC-5001
FRN 012754N/N500016
Hyderabad

DIVI'S LABORATORIES LTD.
HYDERABAD
GACHIBOWLI

For Divi's Laboratories Limited

Place: Hyderabad
Date: August 01, 2026

Dr. Kiran S Divi
Whole-time Director and Chief Executive Officer

Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
M/s Divi's Laboratories Limited
Divi Towers, 1-72/23(P)/303,
Cyber Hills, Gachibowli,
Hyderabad, 500032

1. We have reviewed the standalone unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended June 30, 2026, which are included in the accompanying "Statement of Standalone Unaudited Financial Results for the quarter ended June 30, 2026" (the "Standalone Statement"). The Standalone Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. This Standalone Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Standalone Statement based on our review.

2. We conducted our review of the Standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Standalone Statement has not been prepared in all material respects in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016

N.K. Varadarajan
Partner

Membership Number	: 90196
UDIN	: 26090196DKUQIF1056
Place of signature	: Hyderabad
Date	: August 01, 2026

DIVI'S LABORATORIES LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2026

(₹ in Crores)

S. No	Particulars	Quarter ended			Year ended
		30.06.2026 (Unaudited)	31.03.2026 (Audited)**	30.06.2025 (Unaudited)	31.03.2026 (Audited)
1	**Income**				
	Revenue from operations	**3080**	2831	2410	10560
	Other income	**64**	155	119	507
	Total income	**3144**	2986	2529	11067
2	**Expenses**				
	a) Cost of materials consumed	**1503**	1214	1010	4378
	b) Purchases of stock-in-trade	**-**	-	-	-
	c) Changes in inventories of finished goods, work-in- progress and stock-in-trade	**(517)**	(95)	(54)	(285)
	d) Employee benefits expense	**408**	381	340	1442
	e) Depreciation and amortization expense	**133**	120	112	463
	f) Finance costs	**6**	6	3	23
	g) Other expenses	**431**	397	385	1584
	Total expenses	**1964**	2023	1796	7605
3	**Profit before exceptional items and tax (1-2)**	**1180**	963	733	3462
4	Exceptional items - Impact of new Labour codes	**-**	-	-	74
5	**Profit before tax (3-4)**	**1180**	963	733	3388
6	Tax expense				
	a) Current tax	**291**	249	191	868
	b) Deferred tax	**(13)**	(37)	(3)	(48)
	Total tax expense	**278**	212	188	820
7	**Profit for the period (5-6)**	**902**	751	545	2568
8	Profit for the period attributable to:				
	Shareholders of the Company	**902**	751	545	2568
	Non-controlling interest	**-**	-	-	-
9	**Other comprehensive income:**				
	a) Items that will not be reclassified to profit or loss:				
	i) Gain/(loss) on Remeasurement of post-employment benefit obligations	**2**	(8)	(1)	8
	ii) Income tax relating to the above	**(1)**	2	-*	(2)
	b) Items that will be reclassified to profit or loss:				
	i) Gain on exchange differences in translating the financial statements of foreign operations	**1**	7	4	20
	ii) Income tax relating to the above	**-***	(2)	-*	(5)
	Total Other comprehensive income/(loss) (a+b)	**2**	(1)	3	21
10	Total Other comprehensive income for the period attributable to:				
	Shareholders of the Company	**2**	(1)	3	21
	Non-controlling interest	**-**	-	-	-
11	**Total comprehensive income for the period (7+9)**	**904**	750	548	2589
12	Total comprehensive income for the period attributable to:				
	Shareholders of the company	**904**	750	548	2589
	Non-controlling interest	**-**	-	-	-
13	Paid-up Equity Share Capital	**53**	53	53	53
14	Other equity excluding revaluation reserves				16708
15	**Earnings per Share # (of Rs.2/- each) (not annualized)**				
	a) Basic (Rs.)	**33.95**	28.31	20.49	96.75
	b) Diluted (Rs.)	**33.95**	28.31	20.49	96.75

Contd...

Earnings per share calculated on actual amount of profit after tax in rupees

* Amount is below the rounding off norms adopted by the group.

Price Waterhouse Chartered Accountants LLP
FRN 012754N/N500016
★ Hyderabad ★

DIVI'S LABORATORIES LTD.
GACHIBOWLI

NOTES:

1. The above Statement of consolidated unaudited financial results for the quarter ended 30th June, 2026 ("Consolidated statement") is prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Consolidated statement has been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on August 01, 2026. The statutory auditors have carried out a limited review of the Consolidated statement and issued an unmodified report thereon.
2. The consolidated financial results include the financial results of Divi's Laboratories Limited and its wholly owned subsidiaries Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG (Referred as the "Group").
3. The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reporting business segment as per Ind AS 108.
4. The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only.
5. **Financial results for the quarter ended 31.03.2026 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year, which were subjected to limited review.
6. Details of Forex gain/(loss) are as given below:

(₹ in Crores)

	Quarter Ended			Year Ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
Forex gain/(loss)	**(7)**	90	39	211

Forex gain has been included in other income and loss has been included in other expenses.

Waterhouse Chartered Accountants LLP
LLPIN AAC-5001
FRN 012754N/N500016
Hyderabad

For Divi's Laboratories Limited

Place: Hyderabad
Date: August 01, 2026

Dr. Kiran S Divi
Whole-time Director and Chief Executive Officer

DIVI'S LABORATORIES LTD.
HYDERABAD-33
GACHIBOWLI

Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
M/s Divi's Laboratories Limited
Divi Towers, 1-72/23(P)/303,
Cyber Hills, Gachibowli,
Hyderabad, 500032

1. We have reviewed the consolidated unaudited financial results of Divi's Laboratories Limited (the "Parent") and its subsidiaries (the Parent and its subsidiaries hereinafter referred to as the "Group"), (refer Note 2 on the Consolidated Statement) for the quarter ended June 30, 2026 which are included in the accompanying "Statement of Consolidated Unaudited Financial Results for the quarter ended June 30, 2026" (the "Consolidated Statement"). The Consolidated Statement is being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015") which has been initialled by us for identification purposes.

2. This Consolidated Statement, which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Consolidated Statement based on our review.

3. We conducted our review of the Consolidated Statement in accordance with the Standard on Review Engagements ('SRE') 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Consolidated Statement includes the results of the following entities:
   a) Divis Laboratories (USA) Inc.
   b) Divi's Laboratories Europe AG

Price Waterhouse Chartered Accountants LLP, LLPIN AAC-5001, FRN 012754N/N500016, Hyderabad

Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 44246740

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016

N.K. Varadarajan
Partner

Membership Number	: 90196
UDIN	: 26090196BAZFGH6329
Place of signature	: Hyderabad
Date	: August 01, 2026

DIVI'S LABORATORIES LIMITED

CIN: L24110TG1990PLC011854

Registered Office: 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India, Phone: +91 40 66966300, email: cs@divislabs.com, website: www.divislabs.com

PRESS RELEASE DATED 1st August 2026

Divi's Laboratories earns a Consolidated Total Income of ₹ 3144 Crores for Q1 of Financial Year 2026-27

Consolidated Financial Results

For the quarter ended 30th June 2026

Divi's Laboratories Limited has earned a consolidated total income of ₹ 3,144 crores for the quarter ended 30th June 2026 as against a consolidated total income of ₹ 2,529 crores for the corresponding quarter of the previous financial year. Profit before tax (PBT) for the quarter amounted to ₹ 1,180 crores as against a PBT of ₹ 733 crores for the corresponding quarter of the previous financial year. Profit after tax (PAT) for the quarter amounted to ₹ 902 crores as against a PAT of ₹ 545 crores for the corresponding quarter of the previous financial year.

For the current quarter, we have a forex loss of ₹ 7 crores as against a forex gain of ₹ 39 crores for the corresponding quarter of the previous financial year.

Standalone Financial Results

On a standalone basis, the Company's earnings are as given below:

₹ in crores

Particulars	For the Quarter ended	
	30-06-2026	30-06-2025
Total Income	3037	2476
Profit Before Tax	1165	747
Tax Expense	274	190
Profit After Tax	891	557

Forex gain / loss for the period, on standalone basis, is as given below:

₹ in crores

Particulars	For the Quarter ended	
	30-06-2026	30-06-2025
Forex Gain/(Loss)	(7)	39

Divi's Laboratories Limited

Approved inclusion of Senior Management: **ANNEXURE – I**

S.No	Particulars	Details	
1	Name	**Mr. B. Vara Prasad**	**Mr. J. Srinivasa Rao**
2	Reason for change viz. appointment, re- appointment, resignation, removal, death or otherwise;	Mr. Vara Prasad working as General Manager (Engineering Purchase), has been appointed as Senior Management Personnel with effect from August 01, 2026.	Mr. Srinivasa Rao working as General Manager (Raw Materials Purchase), has been appointed as Senior Management Personnel with effect from August 01, 2026.
3	Date of appointment	August 01, 2026	August 01, 2026
4	Brief profile	Mr. Vara Prasad holds a master's degree in business administration. He joined Divi's Laboratories Limited in the year 1994. With over 31 years of experience in the pharmaceutical industry, he is a highly accomplished Supply Chain and Procurement professional. Over the course of his career, he has played a pivotal role in managing the procurement of high-value capital equipment and in coordinating the development and commissioning of new manufacturing facilities. He brings deep domain expertise in strategic sourcing, vendor management, contract negotiations, and large-scale project execution. He is widely recognized for his ability to lead cross-functional procurement teams and drive key initiatives related to energy-efficient equipment, adoption of new technologies, and sustainable energy systems. He is currently responsible for all engineering related procurement in the Company	Mr. Srinivasa Rao holds a master's degree in business administration. He joined Divi's Laboratories Limited in the year 1995. He is a highly skilled professional with over 30 years of experience in managing and optimizing procurement operations in the pharmaceutical industry. He has proven track record in managing procurement of domestic and import raw materials, annual contracts and leading large procurement team. He has experience in strategic sourcing, vendor development, contract negotiation, regulatory compliance and cross-functional coordination. He is acclaimed for his contributions for implementation of diversified and sustainable supply chain. He is currently responsible for end-to-end raw materials procurement in the Company.
5	Disclosure of relationship between directors	Nil	Nil

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.
Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854
E-mail : mail@divislabs.com, Website : www.divislabs.com